Clinical Trial Update: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations [Phase 2]

View source ↗

Summary

Phase 2 basket trial evaluating tucatinib in combination with trastuzumab across HER2-altered solid tumors, with results posted for several tumor types includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Breast Cancer
• Cervical Cancer
• Non-small Cell Lung Cancer
• Urinary Tract Cancer
• Uterine Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-13